Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma
- 26 November 2016
- journal article
- pharmacoepidemiology and-prescription
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 73 (3) , 357-363
Abstract
Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, is also used to manage seizures in glioblastoma patients. HDAC inhibitors can protect normal cells and tissues from the deleterious effects of radiotherapy, and VPA is reported to improve the survival of glioblastoma patients receiving chemoradiation therapy. VPA also promotes hair growth, and thus has the potential to reduce the radiotherapy side effect of hair loss while improving the survival of patients with glioblastoma. The purpose of this study was to determine whether VPA use during radiotherapy for high-grade glioma is associated with decreased side effects of radiotherapy and an improvement in overall survival (OS) and progression-free survival (PFS). Medical records of 112 patients with high-grade glioma were retrospectively reviewed. We grouped patients by VPA use or non-use during radiotherapy, and evaluated hair loss, OS, and PFS. The radiation dose and fractionation at the onset of hair loss were 4 Gy and two fractions higher, respectively, in the VPA group compared with the VPA non-use group (P < 0.01). Median OS was 42.2 and 20.3 months in the VPA use and non-use groups, respectively (P < 0.01; hazard ratio [HR], 0.36; 95% confidence interval [CI], 0.18–0.74). Median PFS was 22.7 and 11.0 months in the VPA use and non-use groups, respectively (P = 0.099; HR, 0.62; 95% CI, 0.36–1.09). VPA use during radiotherapy for glioma is associated with delayed hair loss and improvement in survival. Hair loss prevention benefits patients suffering from the deleterious effects of radiation.Keywords
This publication has 37 references indexed in Scilit:
- Valproic Acid Induces Hair Regeneration in Murine Model and Activates Alkaline Phosphatase Activity in Human Dermal Papilla CellsPLOS ONE, 2012
- Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastomaNeurology, 2011
- Histone Deacetylase Inhibitors Suppress the Expression of Inflammatory and Innate Immune Response Genes in Human Microglia and AstrocytesJournal of Neuroimmune Pharmacology, 2010
- Autophagy induced by valproic acid is associated with oxidative stress in glioma cell linesNeuro-Oncology, 2009
- Practice Parameter update: Management issues for women with epilepsy—Focus on pregnancy (an evidence-based review): Teratogenesis and perinatal outcomes [RETIRED]Neurology, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Valproic acid induces differentiation and inhibition of proliferation in neural progenitor cells via the beta-catenin-Ras-ERK-p21Cip/WAF1 pathwayBMC Cell Biology, 2008
- Histone Deacetylase Inhibitors Protect against and Mitigate the Lethality of Total-Body Irradiation in MiceRadiation Research, 2008
- Deletion of Histone Deacetylase 3 Reveals Critical Roles in S Phase Progression and DNA Damage ControlMolecular Cell, 2008
- Translating the Histone CodeScience, 2001